INTRODUCTION: We aimed to report the clinically significant prostate cancer (PCa) detection rate in men undergoing magnetic resonance imaging-transrectal ultrasound (MRI-TRUS)-cognitive fusion (CF) targeted biopsies stratified by the Prostate Imaging and Data Reporting System (PI-RADS) version 2 (v2) scores. METHODS: With a quality assurance waiver from the IRB, we identified a cohort of men who underwent MRI-TRUS-CF and synchronous template biopsy from 2015-2017. MRI (PI-RADS v2 score, lesion size, lesion location [peripheral or transition zone (PZ/TZ)]), and CF-TRUS biopsy (operator experience, TRUS visibility, and number of biopsies) features were extracted. The primary outcome was diagnosis of clinically significant (Gleason score ≥3+4=7 or International Society of Urological Pathology (ISUP) grade group ≥2) PCa. RESULTS: During the study period, 131 men (with 142 PIRADS v2 score ≥3 lesions) met inclusion criteria; 98 men had previously negative template biopsy and 33 were on active surveillance for previously detected low-grade PCa. In total, 41.9% (55/131) men had clinically significant PCa - 17.6% (23/131) detected on targeted biopsy only, 8.4% (11/131) on template biopsy only, and 16.0% (21/131) on both targeted and template biopsy. Clinically significant PCa detection stratified by PI-RADS v2 scores were: 11.1% (3/27) for score 3 (indeterminate), 42.9% (24/56) for score 4 (significant cancer likely), and 35.6% (21/59) for score 5 (significant cancer very likely). Clinically significant PCa detection rates in targeted biopsies were better among PZ (41.8% [33/79]) compared to TZ (23.8% [15/63]) lesions (p=0.025) in TRUS visible lesions (p=0.033) and in the most experienced radiologists (p=0.05), with no difference by lesion size or number of additional core biopsies performed (all p>0.05). CONCLUSIONS: Cognitive fusion MRI-TRUS-guided targeted biopsy yielded substantially lower rates of clinically significant cancer in PI-RADS v2 score 4 and 5 lesions when compared to published results using in-bore MR-guided or automated MRI-TRUS fusion guidance systems. Cancer detection was worst for TZ lesions.
INTRODUCTION: We aimed to report the clinically significant prostate cancer (PCa) detection rate in men undergoing magnetic resonance imaging-transrectal ultrasound (MRI-TRUS)-cognitive fusion (CF) targeted biopsies stratified by the Prostate Imaging and Data Reporting System (PI-RADS) version 2 (v2) scores. METHODS: With a quality assurance waiver from the IRB, we identified a cohort of men who underwent MRI-TRUS-CF and synchronous template biopsy from 2015-2017. MRI (PI-RADS v2 score, lesion size, lesion location [peripheral or transition zone (PZ/TZ)]), and CF-TRUS biopsy (operator experience, TRUS visibility, and number of biopsies) features were extracted. The primary outcome was diagnosis of clinically significant (Gleason score ≥3+4=7 or International Society of Urological Pathology (ISUP) grade group ≥2) PCa. RESULTS: During the study period, 131 men (with 142 PIRADS v2 score ≥3 lesions) met inclusion criteria; 98 men had previously negative template biopsy and 33 were on active surveillance for previously detected low-grade PCa. In total, 41.9% (55/131) men had clinically significant PCa - 17.6% (23/131) detected on targeted biopsy only, 8.4% (11/131) on template biopsy only, and 16.0% (21/131) on both targeted and template biopsy. Clinically significant PCa detection stratified by PI-RADS v2 scores were: 11.1% (3/27) for score 3 (indeterminate), 42.9% (24/56) for score 4 (significant cancer likely), and 35.6% (21/59) for score 5 (significant cancer very likely). Clinically significant PCa detection rates in targeted biopsies were better among PZ (41.8% [33/79]) compared to TZ (23.8% [15/63]) lesions (p=0.025) in TRUS visible lesions (p=0.033) and in the most experienced radiologists (p=0.05), with no difference by lesion size or number of additional core biopsies performed (all p>0.05). CONCLUSIONS: Cognitive fusion MRI-TRUS-guided targeted biopsy yielded substantially lower rates of clinically significant cancer in PI-RADS v2 score 4 and 5 lesions when compared to published results using in-bore MR-guided or automated MRI-TRUS fusion guidance systems. Cancer detection was worst for TZ lesions.
Authors: Christopher Lim; Trevor A Flood; Shaheed W Hakim; Wael M Shabana; Jeffrey S Quon; Mohamed El-Khodary; Rebecca E Thornhill; Soufiane El Hallani; Nicola Schieda Journal: J Magn Reson Imaging Date: 2015-08-25 Impact factor: 4.813
Authors: Francesca V Mertan; Matthew D Greer; Joanna H Shih; Arvin K George; Michael Kongnyuy; Akhil Muthigi; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey Journal: J Urol Date: 2016-04-18 Impact factor: 7.450
Authors: Sadhna Verma; Peter L Choyke; Steven C Eberhardt; Aytekin Oto; Clare M Tempany; Baris Turkbey; Andrew B Rosenkrantz Journal: Radiology Date: 2017-11 Impact factor: 11.105
Authors: Nelly Tan; Wei-Chan Lin; Pooria Khoshnoodi; Nazanin H Asvadi; Jeffrey Yoshida; Daniel J A Margolis; David S K Lu; Holden Wu; Kyung Hyun Sung; David Y Lu; Jaioti Huang; Steven S Raman Journal: Radiology Date: 2016-11-18 Impact factor: 11.105
Authors: Satheesh Krishna; Christopher S Lim; Matthew D F McInnes; Trevor A Flood; Wael M Shabana; Robert S Lim; Nicola Schieda Journal: J Magn Reson Imaging Date: 2017-04-07 Impact factor: 4.813
Authors: Christopher S Lim; Matthew D F McInnes; Robert S Lim; Rodney H Breau; Trevor A Flood; Satheesh Krishna; Christopher Morash; Wael M Shabana; Nicola Schieda Journal: J Magn Reson Imaging Date: 2016-11-03 Impact factor: 4.813
Authors: Satheesh Krishna; Matthew McInnes; Christopher Lim; Robert Lim; Shaheed W Hakim; Trevor A Flood; Nicola Schieda Journal: AJR Am J Roentgenol Date: 2017-10-05 Impact factor: 3.959